A detailed history of Eagle Asset Management Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Eagle Asset Management Inc holds 168,795 shares of TGTX stock, worth $4.99 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
168,795
Holding current value
$4.99 Million
% of portfolio
0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.21 - $25.28 $2.9 Million - $4.27 Million
168,795 New
168,795 $3.95 Million
Q1 2024

May 09, 2024

BUY
$13.02 - $21.3 $1.13 Million - $1.85 Million
87,064 New
87,064 $1.32 Million
Q2 2022

Aug 10, 2022

BUY
$3.74 - $10.66 $847,110 - $2.41 Million
226,500 Added 47.67%
701,690 $2.98 Million
Q1 2022

May 12, 2022

BUY
$7.81 - $20.45 $178,356 - $467,016
22,837 Added 5.05%
475,190 $4.52 Million
Q4 2021

Feb 11, 2022

SELL
$15.2 - $35.51 $88,053 - $205,709
-5,793 Reduced 1.26%
452,353 $8.75 Million
Q3 2021

Nov 10, 2021

SELL
$21.78 - $40.45 $8.3 Million - $15.4 Million
-381,108 Reduced 45.41%
458,146 $15.2 Million
Q2 2021

Aug 11, 2021

BUY
$32.5 - $48.96 $250,477 - $377,334
7,707 Added 0.93%
839,254 $32.6 Million
Q1 2021

May 14, 2021

SELL
$41.61 - $54.3 $21.8 Million - $28.5 Million
-524,305 Reduced 38.67%
831,547 $40.7 Million
Q4 2020

Feb 12, 2021

SELL
$25.27 - $54.9 $3.11 Million - $6.75 Million
-122,877 Reduced 8.31%
1,355,852 $70.5 Million
Q3 2020

Nov 12, 2020

BUY
$18.49 - $27.24 $622,687 - $917,361
33,677 Added 2.33%
1,478,729 $38.7 Million
Q2 2020

Aug 12, 2020

BUY
$8.9 - $21.84 $12.9 Million - $31.6 Million
1,445,052 New
1,445,052 $26.8 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Eagle Asset Management Inc Portfolio

Follow Eagle Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Asset Management Inc with notifications on news.